RNA Formulation Resources

31. Insights Into GMP Manufacturing Of RNA-LNP Drug Products 2/29/2024

    Explore key considerations for manufacturing RNA-LNP drug products surrounding process and analytical development, automation, environmental monitoring, and strategic collaborations.

32. Reducing Risk In mRNA Therapeutic Development 8/12/2024

    Advancements in purification, delivery mechanisms, and stability during storage and transport will enable the future of mRNA-based therapies.

33. Delivering The Promise Of Gene Therapy 1/22/2024

    Gene therapies rely on efficient, precise methods of delivering genetic material. Examine how combining polymeric nanoparticles with CRISPR therapies is increasing the potential for improved treatment.

34. How Operational Efficiency Shapes Late-Phase Manufacturability 6/26/2026

    Prioritize operational efficiency over early-stage flexibility to scale advanced therapies. Standardized workflows and qualified shipping lanes reduce variability for predictable late-phase success.

35. Versatile Lipid Nanoparticle Platform For Efficient Gene Editing 6/3/2025

    Lipid nanoparticles enable efficient gene editing in hard-to-transfect cells like T-cells and blood stem cells, which offers scalable, clinically relevant methods for developing advanced therapies for cancer and rare diseases.

36. Enabling Effective Passive And Active Immune Cell Targeting Strategies 8/10/2026

    Targeted LNPs that bypass the liver and home to the spleen could reshape in vivo CAR T cell manufacturing. See the data behind the approach.

37. Why Risk Analysis And Lane Qualification Matter 5/28/2026

    Risk analysis and lane qualification show supply chains perform consistently, meeting regulatory expectations by demonstrating control, reducing variability, and ensuring reliable delivery.

38. Tackling Antimicrobial Resistance 5/14/2024

    Learn how three companies collaborated to develop a new antibiotic to address the increasing development of antimicrobial resistance (AMR) that threatens the global health landscape.

39. Purification And QC Of An RNA 21‑Mer Oligonucleotide Via LC‑MS 1/27/2026

    Learn how buffer choice, gradient strategy, and pretreatment steps influence recovery, purity, and resolution when purifying a native RNA oligo, with analytical confirmation and practical guidance.

40. Turbulent Mixing: Scaling Up Nanoparticle Manufacturing For The Future

    Choosing between turbulent and microfluidic mixing methods in your lipid nanoparticle (LNP) production can have a significant impact when scaling up production.